International

Research Grants 2018

Ayudas para financiar proyectos de investigación básica, clínica o traslacional relacionados con enfermedades e infecciones producidas por hongos, virus y/o parásitos.

• MSCA: Co-funding of Regional, National and International Programmes 2018

CRI Irvington Postdoctoral Fellowships 2018-2

Programa de apoyo a la formación de investigadores en inmunología básica y del cáncer

H2020 Reto Social 1. Salud, cambio demográfico y bienestar 2018.

Topics:

• SC1-BHC-01-2019 (RIA): Understanding causative mechanisms in co- and multimorbidities.
• SC1-BHC-02-2019 (RIA): Systems approaches for the discovery of combinatiorial therapies for complex disorders.
• SC1-BHC-14-2019 (RIA): Stratified host-directed approaches to improve prevention, treatment and/or cure of infectious diseases.
• SC1-BHC-19-2019 (RIA): Implementation research for maternal and child heatlh.
• SC1-BHC-22-2019 (RIA): Mental health in the workplace.
• SC1-BHC-25-2019 (IA): Demonstration pilots for implementation of personalised medice in healthcare.

European Development Clinical Trials Partnership (EDCTP-2):

• Capacity develpment to facilitate delivery and uptake of new or improved medical interventions in african health systems 2018

• Biomakers development 2018-4
• Prevention beyond the pipeline 2018
• Preclinical drug discovery 2018-4
• Accelerate clinical trials (PACT) 2018-4

Albert Renold Travel Fellowship Programme 2018

Ayudas para la movilidad de investigadores encaminadas al aprendizaje de técnicas para la investigación de diabetes

15th Call of Innovative Medicines Initiative – IMI2

Topics under consideration:

• Integrated research platforms enabling patient-centric drug development
• Blockchain enabled healthcare
• Microenvironment imposed signatures in tissue and liquid biopsies in immune mediated disease
• Emerging translational safety technologies and tools for interrogating human immunobiology
• Development and validation of translational platforms in support of synaptopathy drug discovery
• Digital endpoints in neurodegenerative and immune-mediated diseases
• AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries
• AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic

16th Call of Innovative Medicines Initiative – IMI2

Topics:

• Progress new assets (one pre-new molecular entity preNME) and one first-time-in-human (FTIH) start for tuberculosis (TB) that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors.
• Progress nowel assets (one FYIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquilene and cytochrome bc drugs.
• Discover and progress novel assets with new mechanisms of action (one preNME for TB and one preNME for NTM) and biomakers for TB and NTM infection.
• Determination of gepotidacin levels in tonsils and prostatic tissue.
• Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections.
• Functional Ethionamide boosters: a novel combination for tuberculosis therapy.
• Intravenous treatments of serious infections (urinary tract infections (UTI), intra-abdominal infections (IAI) & hospital-acquired pneumonia/ventilator associated pneumonia (HAP/VAP)) caused by Gram(-) bacteria (Enterobacteriacease +/-, Pseudomonas and/or Acinetobacter).

Call for the HBP Infrastructure Voucher Programme: Projects can have, but are not limited to, the following broader goals:

• New software application
• New product or process development
• New customer interface
• New service development